NCT05001945 - Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

September 7, 2022

Study Completion Date

October 7, 2022

Conditions

Hypertension, Renal

Interventions

DRUG

MLS-101 (Part I)

MLS-101 tablet(s) by mouth once or twice daily.

OTHER

Placebo (Part I)

Placebo tablet(s) by mouth once or twice daily.

OTHER

Placebo (Part II)

Placebo tablet(s) by mouth once daily.

DRUG

MLS-101 (Part II)

MLS-101 tablet(s) by mouth once daily.

Trial Locations (44)

11432

Site 141, Jamaica

24551

Site 112, Forest

27203

Site 133, Asheboro

27408

Site 140, Greensboro

27612

Site 150, Raleigh

28210

Site 113, Charlotte

28304

Site 130, Fayetteville

28655

Site 104, Morgantown

30044

Site 125, Lawrenceville

30214

Site 109, Fayetteville

31707

Site 118, Albany

33026

Site 122, Pembroke Pines

33126

Site 146, Miami

33134

Site 105, Coral Gables

33135

Site 137, Miami

Site 139, Miami

33144

Site 143, Miami

33458

Site 134, Jupiter

33467

Site 108, Greenacres City

33765

Site 131, Clearwater

37232

Site 152, Nashville

37421

Site 107, Chattanooga

37660

Site 120, Kingsport

44195

Site 153, Cleveland

57702

Site 115, Rapid City

60005

Site 136, Arlington Heights

63141

Site 121, St Louis

65109

Site 116, Jefferson City

70403

Site 154, Hammond

70458

Site 114, Slidell

71105

Site 148, Shreveport

71111

Site 138, Bossier City

75071

Site 124, McKinney

75149

Site 147, Mesquite

75224

Site 132, Dallas

76012

Site 151, Arlington

76180

Site 128, Richland Hills

77429

Site 145, Cypress

77584

Site 126, Pearland

89121

Site 123, Las Vegas

90502

Site 129, Torrance

91303

Site 102, Tampa

92780

Site 135, Tustin

95648

Site 103, Lincoln